Related Experiment Videos
EGF and dextran-conjugated EGF induces differential phosphorylation of the EGF receptor
Maria Hägg1, Asa Liljegren, Jörgen Carlsson
1Ludwig Institute for Cancer Research, Biomedical Center, SE-751 24 Uppsala, Sweden.
Abstract:
Dextran-conjugated EGF (EGF-dextran) has a potential use for targeted radionuclide therapy of tumors that overexpress the epidermal growth factor receptor (EGFR). There are plans to treat both bladder carcinomas and malignant gliomas with local injections of radiolabeled EGF-dextran since these tumors often express high levels of EGFR. In this report we show that EGF and EGF-dextran differentially activate the EGFR. In the human glioma cell line U-343, activation of the serine/threonine kinases Erk and Akt is identical upon stimulation with EGF or EGF-dextran. However, the effect on phospholipase Cgamma1 (PLCgamma1) phosphorylation differs. In cells stimulated with EGF-dextran, the PLCgamma1 phosphorylation is lower than in cells stimulated with EGF. This observation could be explained by the fact that the PLCgamma1 association sites in the EGFR, tyrosine residues 992 and 1173, were phosphorylated to a lower degree when the receptor was stimulated with EGF-dextran as compared to with EGF.
Insights
Dextran-conjugated EGF (EGF-dextran) shows potential for targeted cancer therapy. While activating key cell signaling pathways similarly to EGF, it results in lower phospholipase Cgamma1 (PLCgamma1) phosphorylation, impacting EGFR signaling.
Area of Science:
- Oncology
- Molecular Biology
- Bioconjugation Chemistry
Background:
- Epidermal Growth Factor Receptor (EGFR) is a target for cancer therapy.
- Dextran-conjugated EGF (EGF-dextran) is being developed for targeted radionuclide therapy.
- EGFR is overexpressed in bladder carcinomas and malignant gliomas.
Purpose of the Study:
- To investigate the differential activation of EGFR by EGF and EGF-dextran.
- To compare the downstream signaling effects of EGF and EGF-dextran.
- To assess the potential impact on targeted cancer therapy efficacy.
Main Methods:
- Utilized human glioma cell line U-343.
- Stimulated cells with EGF and EGF-dextran.
- Analyzed activation of serine/threonine kinases Erk and Akt.
- Measured phospholipase Cgamma1 (PLCgamma1) phosphorylation.
- Assessed phosphorylation of specific tyrosine residues (992 and 1173) on EGFR.
Main Results:
- Both EGF and EGF-dextran identically activated Erk and Akt pathways.
- EGF-dextran stimulation resulted in lower PLCgamma1 phosphorylation compared to EGF.
- Tyrosine residues 992 and 1173 on EGFR, associated with PLCgamma1, showed reduced phosphorylation with EGF-dextran.
Conclusions:
- EGF-dextran differentially modulates EGFR signaling compared to native EGF.
- The reduced PLCgamma1 activation by EGF-dextran may influence its therapeutic efficacy.
- Further studies are warranted to understand the full implications for targeted cancer therapy.